[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"InterValve Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":53},{"warningLetters":4,"total":52},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},172,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-19T05:00:00Z\">02\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjmt-inter-llc-718661-02192026\">JMT Inter LLC\u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jean-Marie Tuete\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>JMT Inter LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>115 Asbury Loop\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19709-8655\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:tuete@jmtinter.com\"> tuete@jmtinter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 718661\u003C\u002Fp>\u003Cp>Dear Mr. Tuete:\u003C\u002Fp>\u003Cp>On August 12, 2025, through September 23, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of JMT Inter LLC located at 115 Asbury Loop, Middletown, DE. FSVP inspections were also conducted by FDA from February 27 through March 20, 2023, and August 13 through August 26, 2024. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safetymodernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on September 23, 2025.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>If requested in writing by FDA, you must send records to the Agency electronically or through another means that delivers the records promptly, rather than making the records available for review at your place of business, as required by 21 CFR 1.510(b)(3) or 21 CFR 1.512(b)(5)(ii)(c) (for Very Small Importers (VSIs)). On August 12, 2025, our Investigator provided you with a Form FDA 482d Request for FSVP Records and spoke with you by telephone on August 25, 2025, and September 9, 2025. During those conversations, you stated your firm classifies as VSI and that you would send your FSVP records. Additionally, our Investigator contacted you multiple times by email between August 12 and September 23, 2025. However, you failed to send records electronically or through another means that delivers the records promptly after receiving our request in writing. As of the date of this letter, we have not received any records from you, including documentation of VSI status or FSVP documents for soft drinks from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>During our inspection, you indicated you choose to comply with the requirements for very small importers and may meet the definition of a “very small importer” under 21 CFR 1.500. If you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required per 21 CFR 1.512(b)(1)(i). You are also still required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (see 21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of your VSI status, a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley.Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 718661 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Theresa Smedley\u003Cbr>Acting Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJean-Marie Tuete\n\nRecipient Title\n\nOwner\n\nJMT Inter LLC\n\n115 Asbury Loop\n\nMiddletown, DE 19709-8655\n\nUnited States\n\ntuete@jmtinter.com\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nWARNING LETTER\nRE: CMS# 718661\nDear Mr. Tuete:\nOn August 12, 2025, through September 23, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of JMT Inter LLC located at 115 Asbury Loop, Middletown, DE. FSVP inspections were also conducted by FDA from February 27 through March 20, 2023, and August 13 through August 26, 2024. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safetymodernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on September 23, 2025.\nYour significant violations of the FSVP regulation are as follows:\nIf requested in writing by FDA, you must send records to the Agency electronically or through another means that delivers the records promptly, rather than making the records available for review at your place of business, as required by 21 CFR 1.510(b)(3) or 21 CFR 1.512(b)(5)(ii)(c) (for Very Small Importers (VSIs)). On August 12, 2025, our Investigator provided you with a Form FDA 482d Request for FSVP Records and spoke with you by telephone on August 25, 2025, and September 9, 2025. During those conversations, you stated your firm classifies as VSI and that you would send your FSVP records. Additionally, our Investigator contacted you multiple times by email between August 12 and September 23, 2025. However, you failed to send records electronically or through another means that delivers the records promptly after receiving our request in writing. As of the date of this letter, we have not received any records from you, including documentation of VSI status or FSVP documents for soft drinks from your foreign supplier (b)(4) located in (b)(4).\nDuring our inspection, you indicated you choose to comply with the requirements for very small importers and may meet the definition of a “very small importer” under 21 CFR 1.500. If you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required per 21 CFR 1.512(b)(1)(i). You are also still required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (see 21 CFR 1.512(b)(3)(i)).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of your VSI status, a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley.Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 718661 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nTheresa Smedley\nActing Program Division Director\nDivision of Northeast Imports","JMT Inter LLC","jmt-inter-llc-718661-02192026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjmt-inter-llc-718661-02192026","2026-10-26T08:09:04.71983+00:00","Warning Letter","Issued","2026-05-12","718661","Food & Beverages","Jean-Marie Tuete","2026-08-19T04:42:40.537+00:00","Via Email","2026-02-19",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},1984,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiosensors-interventional-technologies-pte-ltd-662943-07212023\">Biosensors Interventional Technologies Pte Ltd\u003C\u002Fa>","OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tee Wee Hong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Quality and Regulatory Affairs Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biosensors Interventional Technologies Pte Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>36 Jalan Tukang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>619266\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 21, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hong,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tukang Singapore on April 17 through April 20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the BioFreedom Drug Coated System which is intended for improving coronary luminal diameter in patients at high risk for bleeding for the treatment of de novo lesions in native coronary arteries with a reference diameter ranging between 2.25 mm and 4.0 mm. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm's device, the BioFreedom Drug Coated System is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>We received responses from Mr. Tee Wee Hong, Quality and Regulatory Affairs Director dated May 11, 2023, and June 27, 2023, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example: during the inspection, your firm identified the following two documents as its written MDR procedure.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"Patient Safety Incident Reporting and Recalls\u002FFSCAs\", QS-32, Rev.33, dated 4\u002F19\u002F2023\u003C\u002Fli>\n\t\u003Cli>\"Country Specific Requirements — Patient Safety Incident Reporting\", WI-10570, Rev. 12, dated 4\u002F19\u002F2023\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm is recommended to finalize the establishment of an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of June 28, 2023, your firm does not have such an account. Information about the ESG and enrollment in the eMDR can be found at: How to Enroll in eMDR Program' FDA.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's responses and concluded that it is not adequate. Your response includes your firm's updated documents, namely:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"Product Event Handling\", WI-10610, Rev. 16, dated 4\u002F19\u002F2023\u003C\u002Fli>\n\t\u003Cli>\"Medical Device Reporting, Recalls, Corrections and Removals in US\", WI-11937, Rev. 1, dated 4\u002F19\u002F2023\u003C\u002Fli>\n\t\u003Cli>\"Patient Safety Incident Reporting and Recalls\u002FFSCAs\", QS-32, Rev. 34, dated 5\u002F10\u002F2023\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm's MDR procedures still combine language from the requirements of other regulatory or competent authorities. This might result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803. Additionally, your firm has not yet finalized the establishment of an active ESG production account for the electronic submission of MDR reports.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for complaint CB22-10-004 reasonably suggests that a patient sustained an injury (i.e., acute stent thrombosis) after the implantation of your firm's BioFreedom Drug Coated Coronary Stent system. Subsequently, a balloon dilatation procedure was performed.\u003C\u002Fp>\n\n\u003Cp>The procedure referenced represents medical or surgical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure. There is no information included for the complaint that rules out that the referenced device would not be likely to cause or contribute to the serious injury. As such, the referenced event represents a reportable serious injury event as defined in 21 CFR 803.3. Your firm became aware of the event on October 14, 2022, but the corresponding MDR has not yet been received by the FDA.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm's response dated May 11, 2023, cannot be determined at this time. In the response, your firm states that they conducted a retrospective review of complaints received after the PMA approval on April 14, 2022, and no further reportable events were identified. Additionally, your firm is in the process of establishing an eMDR account to file the referenced event and aligning their MDR reporting process with requirements outlined in the MDR regulations. The effectiveness of the planned corrective actions will be verified once they are implemented. However, your firm has not provided any documentation or evidence indicating completeness of the planned corrective actions as they are still ongoing. The response dated June 27, 2023, does not contain any additional information regarding the noted deficiencies.\u003C\u002Fp>\n\n\u003Cp>3. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, complaint CB23-02-001 reasonably suggests that your firm's BioFreedom Drug Coated Coronary Stent malfunctioned (i.e., dislodgement) while in use. Per the 1995 Preamble, a malfunction is reportable if the malfunction involves a device that is considered to be life-supporting or life-sustaining and thus is essential to maintaining human life. There is no information included for the complaint that justifies that the malfunction would not be likely to cause or contribute to a death or serious injury, if it were to recur. As such, the referenced complaint represents a reportable malfunction event, as defined in 21 CFR 803.3.\u003C\u002Fp>\n\n\u003Cp>Your firm became aware of the event on February 8, 2023, but as of the date of issuance of this letter, the corresponding MDR was not received by the FDA.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm's responses dated May 11, 2023, and June 27, 2023, cannot be determined at this time. In the response, your firm states that they conducted a retrospective review of complaints received after the PMA approval on April 14, 2022, and no further reportable events were identified. Additionally, your firm is in the process of establishing an eMDR account to file the referenced event and aligning their MDR reporting process with requirements outlined in the MDR regulations. The effectiveness of the planned corrective actions will be verified once they are implemented. However, your firm has not provided any documentation or evidence indicating completeness of the planned corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. These violations include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100 (a). For example, your firm has not fully implemented Section 6.7 of its procedure for Corrective and Preventive Action, requiring investigation and requiring determination of the \"root cause\" of the identified quality problem. Specifically,\u003C\u002Fp>\n\n\u003Cp>A. Your firm's CAPA No. 23-0008, initiated 16-MAR-2023, addresses an action limit deviation for air sampling for microorganisms found in the clean room area \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for production of the BioFreedom Drug Coated Stent System. Your firm's investigation is not adequate because it did not include a review of the procedures for qualification of clean rooms, review of records covering qualification of the subject clean room, or a review of your procedure for control of the environment within the clean room. More specifically, your firm did not evaluate procedures for monitoring and control for condition of furniture, the facility, and the HEPA filters. Additionally, your firm's corrective action does not address modification of control limits for temperature within the subject clean room.\u003C\u002Fp>\n\n\u003Cp>B. CAPA No. 22-0006, initiated 21-SEP-2022, addresses an action limit deviation for air sampling for microorganisms found in the clean room area used to produce the catheter portion of your BioFreedom Drug Coated Stent System. Your firm's investigation was inadequate because you did not include a review of the procedures for qualification of clean rooms, a review of records covering qualification of the subject clean room, or a review of your procedure for control of the environment within the clean room. Further, your firm's investigation did not include an evaluation of procedures for monitoring conditions, positioning of furniture, and monitoring and controlling temperature. Your firm's investigation also did not evaluate if there were similar concerns regarding the qualification and control of other clean room areas. Additionally, your firm's corrective action to was not adequate because it did not address modifying the control limits for temperature within the subject clean room.\u003C\u002Fp>\n\n\u003Cp>C. CAPA No. 22-0002, initiated 28-JAN-2022, addresses an \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>during the sterilization process for a load of devices which included your BioFreedom Drug Coated Stent System devices not intended for the U.S. market. These records do not demonstrate a full investigation to determine the causes for this problem, to include review of procedures for vendor evaluation and review of records for the evaluation of the contract sterilizer. Additionally, your firm's records do not demonstrate that your firm identified a corrective action to prevent deviations from the maximum dose identified for the process. Further, your firm's records do not demonstrate retrospective evaluation of any affect the identified problem may have had on the qualification effort for the sterilization process developed for the BioFreedom Drug Coated Stent System devices intended for the U.S. market.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm's responses dated May 11, 2023, and June 27, 2023, cannot be determined because your firm has not completed implementation of their root cause analysis procedure on all open CAPAs. Your firm determined that there was no direct reference of work instruction WI-1 1690 (Root Cause Analysis Tools) to standard operating procedure QS-26 Corrective and Preventive Action Rev 29 Section 6.7, which could lead to ineffective \u002F lack of usage of root cause analysis tools. The use of root cause analysis tool was not made mandatory.\u003C\u002Fp>\n\n\u003Cp>Work instruction WI-1 1689 (Guidelines for Corrective and Preventive Action Forms) does not specify that a retrospective evaluation has to be carried out upon completion of investigation and identification of root cause. As a result, impact to other related products and processes was not assessed. Upon closure of this CAPA, the root cause analysis for all remaining open CAPAs (up till the VOE phase) shall be re-evaluated by the individual CAPA owners based on the requirements in the revised QS-26 Rev 30 and WI-11689 Rev 05. Update F00779 CAPA Action Plan Form \u002F F00780 CAPA Completion Form \u002F F00781 CAPA Verification of Effectiveness Form accordingly if necessary.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure per 21 CFR 820.75(a). Specifically, the firm's current work instruction for the Spray Coating Machine, WI-10726, a process used to apply the drug coating to the stent of the BioFreedom Drug Coated Stent System devices, does not fully define the specifications&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>A. Table 5.9 listing process parameter settings for 6 crown and 9 crown stems features a \"Note\" listing that operator and engineers are permitted to \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameter to achieve&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>B. Section 9.10 of this work instruction lists tables which list the Target, USL (upper specification limit), and LSL (lower specification limit) for In-Process acceptance of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>but this section features a \"Note\" listing that the Engineer&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm's responses dated May 11, 2023, and June 27, 2023, appear to be acceptable. However, you noted in your response that twelve manufacturing procedures (i.e., WI-10726, WI-10784, WI-11357, WI-11239, D00244, D00249, WI-10495, D00361, D00280, D00284, D00285, and WI-10459) have been revised. Be aware that you will need to submit the relevant manufacturing changes to FDA in an appropriate post-approval submission.\u003C\u002Fp>\n\n\u003Cp>Of note, your firm registered for Fiscal Year 2023 on December 6, 2022, but you have not listed the BioFreedom Drug Coated System. Your film listed P190020 and have listed BioFreedom as the proprietary name. Please update your listing to include the full proprietary name (BioFreedom Drug Coated System) for the device to be considered listed. Further, you have not listed any other devices, and this is a requirement if you plan to import other devices to the United States.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case #662943 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Lydia Glaw, Assistant Director of Coronary Interventional Devices at Lydia.Glaw@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D.,\u003Cbr>\nDirector\u003Cbr>\nOHT2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nDebashis Dutta,\u003Cbr>\nUS Agent\u003Cbr>\nBiosensors International USA, Inc.\u003Cbr>\n1104 Philadelphia Pike\u003Cbr>\nWilmington, DE 19809\u003Cbr>\nVia email: D.Dutta@Biosensors.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Tee Wee Hong\n\nRecipient Title\n\nQuality and Regulatory Affairs Director\n\nBiosensors Interventional Technologies Pte Ltd\n\n36 Jalan Tukang\n\n619266\n\nSingapore\n\nIssuing Office:\n\nOHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\n\nUnited States\n\nJuly 21, 2023\n\nWARNING LETTER\n\nDear Mr. Hong,\n\nDuring an inspection of your firm located in Tukang Singapore on April 17 through April 20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the BioFreedom Drug Coated System which is intended for improving coronary luminal diameter in patients at high risk for bleeding for the treatment of de novo lesions in native coronary arteries with a reference diameter ranging between 2.25 mm and 4.0 mm. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nOur inspection revealed that your firm's device, the BioFreedom Drug Coated System is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting.\n\nWe received responses from Mr. Tee Wee Hong, Quality and Regulatory Affairs Director dated May 11, 2023, and June 27, 2023, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a)(1). For example: during the inspection, your firm identified the following two documents as its written MDR procedure.\n\n\"Patient Safety Incident Reporting and Recalls\u002FFSCAs\", QS-32, Rev.33, dated 4\u002F19\u002F2023\n\n\"Country Specific Requirements — Patient Safety Incident Reporting\", WI-10570, Rev. 12, dated 4\u002F19\u002F2023\n\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\n\nAdditionally, your firm is recommended to finalize the establishment of an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports. FDA verified that, as of June 28, 2023, your firm does not have such an account. Information about the ESG and enrollment in the eMDR can be found at: How to Enroll in eMDR Program' FDA.\n\nWe reviewed your firm's responses and concluded that it is not adequate. Your response includes your firm's updated documents, namely:\n\n\"Product Event Handling\", WI-10610, Rev. 16, dated 4\u002F19\u002F2023\n\n\"Medical Device Reporting, Recalls, Corrections and Removals in US\", WI-11937, Rev. 1, dated 4\u002F19\u002F2023\n\n\"Patient Safety Incident Reporting and Recalls\u002FFSCAs\", QS-32, Rev. 34, dated 5\u002F10\u002F2023\n\nYour firm's MDR procedures still combine language from the requirements of other regulatory or competent authorities. This might result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803. Additionally, your firm has not yet finalized the establishment of an active ESG production account for the electronic submission of MDR reports.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\n\nFor example, the information included for complaint CB22-10-004 reasonably suggests that a patient sustained an injury (i.e., acute stent thrombosis) after the implantation of your firm's BioFreedom Drug Coated Coronary Stent system. Subsequently, a balloon dilatation procedure was performed.\n\nThe procedure referenced represents medical or surgical intervention necessary to preclude permanent impairment of a body function or permanent damage to a body structure. There is no information included for the complaint that rules out that the referenced device would not be likely to cause or contribute to the serious injury. As such, the referenced event represents a reportable serious injury event as defined in 21 CFR 803.3. Your firm became aware of the event on October 14, 2022, but the corresponding MDR has not yet been received by the FDA.\n\nThe adequacy of your firm's response dated May 11, 2023, cannot be determined at this time. In the response, your firm states that they conducted a retrospective review of complaints received after the PMA approval on April 14, 2022, and no further reportable events were identified. Additionally, your firm is in the process of establishing an eMDR account to file the referenced event and aligning their MDR reporting process with requirements outlined in the MDR regulations. The effectiveness of the planned corrective actions will be verified once they are implemented. However, your firm has not provided any documentation or evidence indicating completeness of the planned corrective actions as they are still ongoing. The response dated June 27, 2023, does not contain any additional information regarding the noted deficiencies.\n\n3. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, complaint CB23-02-001 reasonably suggests that your firm's BioFreedom Drug Coated Coronary Stent malfunctioned (i.e., dislodgement) while in use. Per the 1995 Preamble, a malfunction is reportable if the malfunction involves a device that is considered to be life-supporting or life-sustaining and thus is essential to maintaining human life. There is no information included for the complaint that justifies that the malfunction would not be likely to cause or contribute to a death or serious injury, if it were to recur. As such, the referenced complaint represents a reportable malfunction event, as defined in 21 CFR 803.3.\n\nYour firm became aware of the event on February 8, 2023, but as of the date of issuance of this letter, the corresponding MDR was not received by the FDA.\n\nThe adequacy of your firm's responses dated May 11, 2023, and June 27, 2023, cannot be determined at this time. In the response, your firm states that they conducted a retrospective review of complaints received after the PMA approval on April 14, 2022, and no further reportable events were identified. Additionally, your firm is in the process of establishing an eMDR account to file the referenced event and aligning their MDR reporting process with requirements outlined in the MDR regulations. The effectiveness of the planned corrective actions will be verified once they are implemented. However, your firm has not provided any documentation or evidence indicating completeness of the planned corrective actions as they are still ongoing.\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to the following:\n\n1. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100 (a). For example, your firm has not fully implemented Section 6.7 of its procedure for Corrective and Preventive Action, requiring investigation and requiring determination of the \"root cause\" of the identified quality problem. Specifically,\n\nA. Your firm's CAPA No. 23-0008, initiated 16-MAR-2023, addresses an action limit deviation for air sampling for microorganisms found in the clean room area (b)(4) used for production of the BioFreedom Drug Coated Stent System. Your firm's investigation is not adequate because it did not include a review of the procedures for qualification of clean rooms, review of records covering qualification of the subject clean room, or a review of your procedure for control of the environment within the clean room. More specifically, your firm did not evaluate procedures for monitoring and control for condition of furniture, the facility, and the HEPA filters. Additionally, your firm's corrective action does not address modification of control limits for temperature within the subject clean room.\n\nB. CAPA No. 22-0006, initiated 21-SEP-2022, addresses an action limit deviation for air sampling for microorganisms found in the clean room area used to produce the catheter portion of your BioFreedom Drug Coated Stent System. Your firm's investigation was inadequate because you did not include a review of the procedures for qualification of clean rooms, a review of records covering qualification of the subject clean room, or a review of your procedure for control of the environment within the clean room. Further, your firm's investigation did not include an evaluation of procedures for monitoring conditions, positioning of furniture, and monitoring and controlling temperature. Your firm's investigation also did not evaluate if there were similar concerns regarding the qualification and control of other clean room areas. Additionally, your firm's corrective action to was not adequate because it did not address modifying the control limits for temperature within the subject clean room.\n\nC. CAPA No. 22-0002, initiated 28-JAN-2022, addresses an (b)(4) during the sterilization process for a load of devices which included your BioFreedom Drug Coated Stent System devices not intended for the U.S. market. These records do not demonstrate a full investigation to determine the causes for this problem, to include review of procedures for vendor evaluation and review of records for the evaluation of the contract sterilizer. Additionally, your firm's records do not demonstrate that your firm identified a corrective action to prevent deviations from the maximum dose identified for the process. Further, your firm's records do not demonstrate retrospective evaluation of any affect the identified problem may have had on the qualification effort for the sterilization process developed for the BioFreedom Drug Coated Stent System devices intended for the U.S. market.\n\nThe adequacy of your firm's responses dated May 11, 2023, and June 27, 2023, cannot be determined because your firm has not completed implementation of their root cause analysis procedure on all open CAPAs. Your firm determined that there was no direct reference of work instruction WI-1 1690 (Root Cause Analysis Tools) to standard operating procedure QS-26 Corrective and Preventive Action Rev 29 Section 6.7, which could lead to ineffective \u002F lack of usage of root cause analysis tools. The use of root cause analysis tool was not made mandatory.\n\nWork instruction WI-1 1689 (Guidelines for Corrective and Preventive Action Forms) does not specify that a retrospective evaluation has to be carried out upon completion of investigation and identification of root cause. As a result, impact to other related products and processes was not assessed. Upon closure of this CAPA, the root cause analysis for all remaining open CAPAs (up till the VOE phase) shall be re-evaluated by the individual CAPA owners based on the requirements in the revised QS-26 Rev 30 and WI-11689 Rev 05. Update F00779 CAPA Action Plan Form \u002F F00780 CAPA Completion Form \u002F F00781 CAPA Verification of Effectiveness Form accordingly if necessary.\n\n2. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure per 21 CFR 820.75(a). Specifically, the firm's current work instruction for the Spray Coating Machine, WI-10726, a process used to apply the drug coating to the stent of the BioFreedom Drug Coated Stent System devices, does not fully define the specifications (b)(4)\n\nA. Table 5.9 listing process parameter settings for 6 crown and 9 crown stems features a \"Note\" listing that operator and engineers are permitted to (b)(4) parameter to achieve (b)(4)\n\nB. Section 9.10 of this work instruction lists tables which list the Target, USL (upper specification limit), and LSL (lower specification limit) for In-Process acceptance of (b)(4) but this section features a \"Note\" listing that the Engineer (b)(4)\n\nYour firm's responses dated May 11, 2023, and June 27, 2023, appear to be acceptable. However, you noted in your response that twelve manufacturing procedures (i.e., WI-10726, WI-10784, WI-11357, WI-11239, D00244, D00249, WI-10495, D00361, D00280, D00284, D00285, and WI-10459) have been revised. Be aware that you will need to submit the relevant manufacturing changes to FDA in an appropriate post-approval submission.\n\nOf note, your firm registered for Fiscal Year 2023 on December 6, 2022, but you have not listed the BioFreedom Drug Coated System. Your film listed P190020 and have listed BioFreedom as the proprietary name. Please update your listing to include the full proprietary name (BioFreedom Drug Coated System) for the device to be considered listed. Further, you have not listed any other devices, and this is a requirement if you plan to import other devices to the United States.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's responses and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #662943 when replying. If you have any questions about the contents of this letter, please contact: Lydia Glaw, Assistant Director of Coronary Interventional Devices at Lydia.Glaw@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D.,\n\nDirector\n\nOHT2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nDebashis Dutta,\n\nUS Agent\n\nBiosensors International USA, Inc.\n\n1104 Philadelphia Pike\n\nWilmington, DE 19809\n\nVia email: D.Dutta@Biosensors.com","Biosensors Interventional Technologies Pte Ltd","biosensors-interventional-technologies-pte-ltd-662943-07212023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiosensors-interventional-technologies-pte-ltd-662943-07212023","2026-10-26T08:08:05.464922+00:00","2023-07-25","662943","Medical Devices","Mr. Tee Wee Hong","2026-08-20T00:51:21.477+00:00","2023-07-21",2,{"510k":54,"classification":55,"enforcement":56,"event":57,"event_backfill":58,"pma":59,"warning_letter":60},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]